Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Jon C. Ogg | Apr 23, 2014 at 1:35 PM EDT

Lombard Signals More Evidence of IPO Market Reality Check

Jon OggThe market for initial public offerings was getting to be a bit ridiculous. Now that volatility has returned in…

Jon C. Ogg | Apr 23, 2014 at 10:50 AM EDT

Companies Betting on the Next 10 Blockbuster Drugs

24/7 Wall St. wanted to evaluate the prospects for several would-be blockbuster drugs. Some of these have approvals already in…

Jon C. Ogg | Apr 23, 2014 at 8:50 AM EDT

UBS Top Stocks to Buy Working for Cancer Cures

In a new research report, the Healthcare team at UBS took an in-depth look at the top companies that are…

Jon C. Ogg | Apr 22, 2014 at 4:48 PM EDT

An Earnings Tale of Two Biotechs: Gilead vs. Amgen

ThinkstockGilead Sciences Inc. (NASDAQ: GILD) and Amgen Inc. (NASDAQ: AMGN) have both reported earnings. This is a definite difference in…

Jon C. Ogg | Apr 22, 2014 at 12:00 PM EDT

Biotech Earnings Previews: Amgen, Biogen Idec, Gilead, Celgene

ThinkstockBiotech stocks took it on the chin during the sell-off. In fact, biotech stocks may have even led the sell-off…

Jon C. Ogg | Apr 22, 2014 at 10:40 AM EDT

GW Pharma Dual Cannabinoid Endorsement: Morgan Stanley and Jim Cramer

GW Pharmaceuticals is far from your typical pharma or biotech stock. It is also far from your typical legalized marijuana…

Trey Thoelcke | Apr 22, 2014 at 9:50 AM EDT

Jefferies Initiates Coverage on Specialty Pharmaceutical Takeover Candidates

The specialty pharmaceutical sector is exploding with news of takeovers, exchanges and possible mergers. Here are some of the top…

Jon C. Ogg | Apr 21, 2014 at 1:25 PM EDT

What a Combined Pfizer and AstraZeneca Would Look Like, and Face

ThinkstockIt is not that common that you hear about mergers in the $50 billion range. But what about when you…

Paul Ausick | Apr 21, 2014 at 10:10 AM EDT

Odds of Sarepta Drug Approval Rise Sharply

Shares of Sarepta Therapeutics went through the roof Monday morning following an announcement that it plans to have a New…

Trey Thoelcke | Apr 21, 2014 at 9:05 AM EDT

J.P. Morgan’s Top Biotech and Health Care Picks With Huge Upside

In a new research report, the J.P. Morgan health care team highlights their top names to buy after the sell-off…

Paul Ausick | Apr 18, 2014 at 8:20 AM EDT

Obamacare Sign-Ups Top 8 Million

ThinkstockAt a press conference on Thursday afternoon, President Obama announced that the number of Americans using the public exchanges to…

Trey Thoelcke | Apr 17, 2014 at 7:30 AM EDT

UnitedHealth Group Revenues Stung by Obamacare

UnitedHealth Group reported better-than-expected first-quarter earnings before markets opened Thursday, but revenues fell short of consensus estimates.

Paul Ausick | Apr 16, 2014 at 1:05 PM EDT

Medical Device Maker’s IPO a Modest Success

ThinkstockSome initial public offerings (IPOs) are considered a huge success if the stock appreciates more than about 20% on its…

Jon C. Ogg | Apr 16, 2014 at 10:40 AM EDT

Why Lpath Could Rise 300%

Canaccord Genuity is one of the few firms that are willing to cover small-cap biotech and emerging pharma stocks. Sometimes…

Paul Ausick | Apr 15, 2014 at 8:30 AM EDT

Johnson & Johnson Earnings Point to New 52-Week High

Johnson & Johnson reported better-than-expected first-quarter results before markets opened Tuesday morning. And the company boosted its earnings guidance for…

1 … 288 289 290 291 292 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Lombard Signals More Evidence of IPO Market Reality Check

Companies Betting on the Next 10 Blockbuster Drugs

UBS Top Stocks to Buy Working for Cancer Cures

An Earnings Tale of Two Biotechs: Gilead vs. Amgen

Biotech Earnings Previews: Amgen, Biogen Idec, Gilead, Celgene

GW Pharma Dual Cannabinoid Endorsement: Morgan Stanley and Jim Cramer

Jefferies Initiates Coverage on Specialty Pharmaceutical Takeover Candidates

What a Combined Pfizer and AstraZeneca Would Look Like, and Face

Odds of Sarepta Drug Approval Rise Sharply

J.P. Morgan’s Top Biotech and Health Care Picks With Huge Upside

Obamacare Sign-Ups Top 8 Million

UnitedHealth Group Revenues Stung by Obamacare

Medical Device Maker’s IPO a Modest Success

Why Lpath Could Rise 300%

Johnson & Johnson Earnings Point to New 52-Week High

Bitcoin Price Hits $80K: We Asked Grok If BTC Could Hold $80K in May

This High-Yield Bond ETF Offers Steady Cash Flow and Low Volatility

This Natural Resources ETF Has Silently Outperformed The S&P 500 Year-To-Date While Yielding 5%

39% of Americans Are Betting on Crypto and Prediction Markets Instead of Saving

A $300,000 Annuity Guarantees $1,900 a Month for Life, but Here Is What Retirees Are Giving Up

Bitcoin Price Hits $80K: We Asked Grok If BTC Could Hold $80K in May

This High-Yield Bond ETF Offers Steady Cash Flow and Low Volatility

Health and Healthcare Articles

All Health and Healthcare Articles

Lombard Signals More Evidence of IPO Market Reality Check

Companies Betting on the Next 10 Blockbuster Drugs

UBS Top Stocks to Buy Working for Cancer Cures

An Earnings Tale of Two Biotechs: Gilead vs. Amgen

Biotech Earnings Previews: Amgen, Biogen Idec, Gilead, Celgene

GW Pharma Dual Cannabinoid Endorsement: Morgan Stanley and Jim Cramer

Jefferies Initiates Coverage on Specialty Pharmaceutical Takeover Candidates

What a Combined Pfizer and AstraZeneca Would Look Like, and Face

Odds of Sarepta Drug Approval Rise Sharply

J.P. Morgan’s Top Biotech and Health Care Picks With Huge Upside

Obamacare Sign-Ups Top 8 Million

UnitedHealth Group Revenues Stung by Obamacare

Medical Device Maker’s IPO a Modest Success

Why Lpath Could Rise 300%

Johnson & Johnson Earnings Point to New 52-Week High

Bitcoin Price Hits $80K: We Asked Grok If BTC Could Hold $80K in May

This High-Yield Bond ETF Offers Steady Cash Flow and Low Volatility

This Natural Resources ETF Has Silently Outperformed The S&P 500 Year-To-Date While Yielding 5%

Featured Reads

39% of Americans Are Betting on Crypto and Prediction Markets Instead of Saving

A $300,000 Annuity Guarantees $1,900 a Month for Life, but Here Is What Retirees Are Giving Up